WATAG Advisory Note Approval for formulary listing of omalizumab (Xolair ®) WATAG advises that omalizumab is hereby approved for listing and hospital use in a highly targeted population of adult or adolescent patients w - Cromoglicic acid - Document - PDFSEARCH.IO

First Page	Meta Content
	WATAG Advisory Note Approval for formulary listing of omalizumab (Xolair ®) WATAG advises that omalizumab is hereby approved for listing and hospital use in a highly targeted population of adult or adolescent patients w Add to Reading List Document Date: 2014-10-28 02:27:30 Open Document File Size: 102,94 KB Share Result on Facebook Facility hospital Drug / / MedicalCondition severe persistent asthma / correct drug usage / severe persistent allergic asthma / severe asthma / Frequent severe asthma / Allergic asthma / Severe / persistent asthma / asthma / / Organization Drug and Therapeutics Committee / / Position physician / / Product Xolair / Prednisolone / / SocialTag Respiratory therapy Monoclonal antibodies Omalizumab Asthma Organochlorides Immunology Allergy Cromoglicic acid Montelukast Pulmonology

WATAG Advisory Note Approval for formulary listing of omalizumab (Xolair ®) WATAG advises that omalizumab is hereby approved for listing and hospital use in a highly targeted population of adult or adolescent patients wAdd to Reading List